544 related articles for article (PubMed ID: 23457383)
1. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
Genovese MC; Rubbert-Roth A; Smolen JS; Kremer J; Khraishi M; Gómez-Reino J; Sebba A; Pilson R; Williams S; Van Vollenhoven R
J Rheumatol; 2013 Jun; 40(6):768-80. PubMed ID: 23457383
[TBL] [Abstract][Full Text] [Related]
2. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
Baek HJ; Lim MJ; Park W; Park SH; Shim SC; Yoo DH; Kim HA; Lee SK; Lee YJ; Park YE; Cha HS; Song YW
Korean J Intern Med; 2019 Jul; 34(4):917-931. PubMed ID: 29334721
[TBL] [Abstract][Full Text] [Related]
4. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Takei S; Tanaka Y; Sano Y; Yaguramaki H; Yamanaka H
J Rheumatol; 2014 Jan; 41(1):15-23. PubMed ID: 24187110
[TBL] [Abstract][Full Text] [Related]
6. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
Kivitz A; Olech E; Borofsky MA; Zazueta B; Navarro-Sarabia F; Radominski SC; Merrill JT; Pacheco-Tena C; Pei J; Nasmyth-Miller C; Pope JE
J Rheumatol; 2018 Apr; 45(4):456-464. PubMed ID: 29247149
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
Bykerk VP; Östör AJK; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Nurmohamed MT; Luder Y; Sidiropoulos PNM; Devenport J; Sibilia J
Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
Abdulkader OAF; Qushmaq K; Aljishi F
Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
Yazici Y; Curtis JR; Ince A; Baraf H; Malamet RL; Teng LL; Kavanaugh A
Ann Rheum Dis; 2012 Feb; 71(2):198-205. PubMed ID: 21949007
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
Kremer JM; Blanco R; Halland AM; Brzosko M; Burgos-Vargas R; Mela CM; Rowell L; Fleischmann RM
Clin Exp Rheumatol; 2016; 34(4):625-33. PubMed ID: 27087059
[TBL] [Abstract][Full Text] [Related]
11. Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.
Khawaja MN; Bergman MJ; Yourish J; Pei J; Reiss W; Keystone E
Arthritis Care Res (Hoboken); 2017 May; 69(5):609-615. PubMed ID: 27564431
[TBL] [Abstract][Full Text] [Related]
12. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
13. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan.
Yamamoto K; Goto H; Hirao K; Nakajima A; Origasa H; Tanaka K; Tomobe M; Totsuka K
J Rheumatol; 2015 Aug; 42(8):1368-75. PubMed ID: 26034149
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre.
Addimanda O; Possemato N; Macchioni P; Salvarani C
Clin Exp Rheumatol; 2014; 32(4):460-4. PubMed ID: 24960220
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
[TBL] [Abstract][Full Text] [Related]
16. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.
Nakashima Y; Kondo M; Fukuda T; Harada H; Horiuchi T; Ishinishi T; Jojima H; Kuroda K; Miyahara H; Maekawa M; Nishizaka H; Nagamine R; Nakashima H; Otsuka T; Shono E; Suematsu E; Shimauchi T; Tsuru T; Wada K; Yoshizawa S; Yoshizawa S; Iwamoto Y
Mod Rheumatol; 2014 Mar; 24(2):258-64. PubMed ID: 24593201
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.
Navarro G; Taroumian S; Barroso N; Duan L; Furst D
Semin Arthritis Rheum; 2014 Feb; 43(4):458-69. PubMed ID: 24262929
[TBL] [Abstract][Full Text] [Related]
18. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice.
Bykerk VP; Ostör AJ; Alvaro-Gracia J; Pavelka K; Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Stancati A; Sibilia J
Ann Rheum Dis; 2012 Dec; 71(12):1950-4. PubMed ID: 22615456
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
